Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2017-04-03 Board/Management Inform…
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Directorate Change
Board/Management Information Classification · 100% confidence The document is an official announcement from Evgen Pharma plc regarding the resignation of a Non-Executive Director, Mark Wyatt. The title 'Directorate Change' and the content detailing the departure of a board member directly align with the definition for 'Board/Management Information'.
2017-04-03 English
Further US Patent Grant
Regulatory Filings Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding a patent grant for Evgen Pharma PLC. It does not fit into specific categories like financial reports, dividends, or management changes. As it is a general regulatory announcement regarding company operations and intellectual property, it falls under the RNS category.
2017-03-28 English
Issue of Equity, PDMR Shareholding and TVR
Regulatory Filings Classification · 98% confidence The document is an RNS announcement from Evgen Pharma PLC regarding the issuance of new equity due to the exercise of options, including a mention of a Director/PDMR shareholding change and an update to total voting rights. While it mentions director shareholding, the primary purpose is the issuance of new shares (capital change). According to the filing definitions, 'SHA' covers announcements regarding new share issues and capital changes, which is the core event described here.
2017-03-06 English
Patent Grant in the United States
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces the granting of a patent in the United States for the company's lead product, SFX-01. Since this is a corporate announcement regarding operational/intellectual property developments that does not fit into specific categories like financial reports, dividends, or M&A, it falls under the general regulatory filing category.
2017-02-14 English
Services Agreement with APTrans
Regulatory Filings Classification · 100% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a new services agreement between Evgen Pharma and APTrans. Since this is a general corporate announcement regarding business operations and partnerships that does not fit into specific categories like M&A, financial results, or director dealings, it falls under the RNS (Regulatory Filings) category.
2017-02-13 English
Half Yearly Report
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim results' report for the six months ended 30 September 2016 for Evgen Pharma PLC. It contains detailed financial highlights, a Chairman's and Chief Executive's statement, and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2016
2016-12-05 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.